Alzheimer’s disease has a history stretching back more than a century, from a single puzzling case in a Frankfurt psychiatric clinic to a global research effort involving billions of dollars and millions of patients. The story traces how a mysterious form of dementia went from an obscure clinical curiosity to the most common neurodegenerative disease in the world, and how scientists slowly pieced together the biological machinery behind it.
The First Patient: Auguste Deter
In November 1901, a 51-year-old woman named Auguste Deter was admitted to a psychiatric facility in Frankfurt, Germany. Her symptoms were striking for someone so young: severe memory loss, confusion, unpredictable behavior, and difficulty speaking. Her physician, a psychiatrist named Alois Alzheimer, documented her decline in careful clinical notes. By July 1905, Deter was completely withdrawn, silent, lying curled in bed, incontinent, losing weight, and suffering from bedsores. She died in April 1906.
What happened next changed medicine. Alzheimer performed an autopsy on Deter’s brain and examined the tissue under a microscope. He found two abnormalities that had never been described together in this way: dense clumps of material scattered between nerve cells (which would later be called plaques) and twisted fibers inside the nerve cells themselves (later named neurofibrillary tangles). In November 1906, Alzheimer presented these findings at a medical conference in Tübingen, Germany. The reaction from fellow psychiatrists was lukewarm. Few grasped the significance of what he was describing.
Within a few years, however, other physicians began identifying similar cases. Emil Kraepelin, one of the most influential psychiatrists of the era and Alzheimer’s colleague, gave the condition its name in a 1910 textbook, calling it “Alzheimer’s disease.” For decades afterward, it was considered a rare form of “presenile dementia,” something that struck people unusually young. The far more common memory loss of old age was simply called senility and largely dismissed as a normal part of aging.
Decades in the Shadows
From the 1910s through the 1960s, Alzheimer’s disease received remarkably little scientific attention. Dementia in older adults was not seen as a disease worth studying. It was just what happened when people got old. The plaques and tangles Alzheimer had described were known to pathologists, but no one understood what they were made of or why they formed. Research funding was minimal, and there was no organized patient advocacy.
That began to shift in the 1970s, when researchers started arguing that the dementia affecting millions of elderly people was not a normal consequence of aging but a specific disease process, biologically identical to what Alzheimer had described in younger patients. This reframing was enormous. It meant Alzheimer’s disease was not rare at all. It was, in fact, one of the most common diseases of later life, and it needed the kind of serious scientific investigation that cancer and heart disease were already receiving.
The Rise of Patient Advocacy
In 1980, a Chicago businessman named Jerome Stone, along with a group of family caregivers, founded the Alzheimer’s Association. Stone, who served as its president from 1980 to 1988 and remained its honorary chair until 2015, understood that families dealing with the disease were isolated, overwhelmed, and had no organized voice. The Association quickly became a powerful force in raising public awareness, funding research, and pressuring the federal government to invest in the science. It helped transform Alzheimer’s from a condition families quietly endured into a public health priority.
Cracking the Biology: Amyloid and Tau
The 1980s brought the breakthroughs that would define Alzheimer’s research for the next four decades. In 1984, George Glenner and Caine Wong isolated and partially sequenced a small protein from the brains of Alzheimer’s patients. This protein, called amyloid beta, turned out to be the main ingredient in the plaques that Alois Alzheimer had first seen under his microscope nearly 80 years earlier. Glenner and Wong’s discovery is now considered a turning point in modern Alzheimer’s research because it gave scientists a specific molecular target to study.
Two years later, in 1986, a team led by Iqbal Grundke-Iqbal and Khalid Iqbal identified the protein responsible for the other hallmark of the disease: the neurofibrillary tangles. They showed that a protein called tau, which normally helps maintain the internal structure of nerve cells, was abnormally modified in Alzheimer’s brains. This altered tau clumped together into the twisted fibers that Alzheimer had described. With both proteins now identified, the field had two concrete biological targets, and a fierce (and still ongoing) debate began over which one was more important in driving the disease.
The amyloid camp gained the upper hand through much of the 1990s and 2000s, giving rise to what became known as the “amyloid hypothesis”: the idea that a buildup of amyloid beta in the brain is the initial trigger, with tau tangles, nerve cell death, and cognitive decline following as downstream consequences. This hypothesis guided the vast majority of drug development efforts for the next 30 years.
Genetics Enter the Picture
In 1993, researchers at the Duke University Alzheimer’s Disease Research Center published a series of papers linking a specific gene variant to the most common form of the disease. The gene, called APOE, comes in several versions. One version, known as APOE-e4, significantly increases a person’s risk of developing late-onset Alzheimer’s, the form that appears after age 65. Carrying one copy of APOE-e4 roughly triples the risk; carrying two copies can increase it tenfold or more.
This was a landmark finding because it showed that genetics played a clear role even in the “ordinary” form of Alzheimer’s that strikes in old age, not just the rare early-onset cases that had already been linked to specific gene mutations. APOE-e4 remains the strongest known genetic risk factor for late-onset Alzheimer’s, though it is not deterministic. Many carriers never develop the disease, and many patients don’t carry the variant at all.
The First Treatments and a Long Drought
The 1990s also saw the first drugs approved to treat Alzheimer’s symptoms. A class of medications called cholinesterase inhibitors, including donepezil (Aricept), worked by boosting levels of a chemical messenger involved in memory and learning. These drugs could modestly improve symptoms or slow their progression for a time, but they did not stop the underlying disease. In 2003, a drug called memantine became the first medication approved for moderate-to-severe Alzheimer’s, working through a different brain signaling pathway.
And then, for nearly two decades, nothing new was approved. The period from the mid-2000s through the early 2020s was defined by a staggering rate of failure. Hundreds of clinical trials tested drugs designed to clear amyloid, block tau, reduce inflammation, or protect nerve cells. Almost all of them failed, leading many scientists to question whether the amyloid hypothesis was wrong, or at least incomplete. Billions of dollars in research investment produced no new treatments. For patients and families, it was a deeply frustrating era.
How Diagnosis Evolved
For most of its history, Alzheimer’s could only be confirmed after death, through autopsy. The original diagnostic criteria, published in 1984 by a joint task force (known as NINCDS-ADRDA), required a diagnosis of dementia based on clinical symptoms. Biomarkers like blood tests or brain scans were used only to rule out other possible causes, not to confirm Alzheimer’s itself. A “definite” diagnosis required examining brain tissue under a microscope.
In 2011, the National Institute on Aging and the Alzheimer’s Association released updated criteria that fundamentally changed this approach. For the first time, the new framework incorporated brain imaging and spinal fluid tests that could detect amyloid plaques and tau tangles in living patients. This shifted biomarkers from a tool for excluding other diseases to a tool for confirming Alzheimer’s directly. The 2011 criteria also recognized that Alzheimer’s exists on a spectrum: it begins with a long “preclinical” phase where brain changes are underway but no symptoms are noticeable, progresses through a “prodromal” stage of mild cognitive impairment, and eventually reaches full dementia. This was a pivotal conceptual shift, acknowledging that the disease starts years or even decades before memory loss becomes obvious.
A New Generation of Drugs
After years of failure, the tide began to turn in the early 2020s. A new generation of antibody-based drugs designed to remove amyloid plaques from the brain finally showed measurable benefits in large clinical trials. In July 2024, the FDA approved donanemab (sold as Kisunla), an intravenous treatment for adults with Alzheimer’s disease. In a trial of more than 1,700 patients, those receiving the drug showed a statistically significant reduction in cognitive and functional decline compared to those on placebo over 76 weeks. The benefits were modest in absolute terms, but they represented something the field had never achieved: a treatment that slowed the actual progression of the disease, not just its symptoms.
These approvals validated, at least partially, the amyloid hypothesis that had guided research since the 1980s. They also came with serious caveats. The drugs carry risks of brain swelling and small brain bleeds, require regular monitoring with brain scans, and work best in people with early-stage disease. They slow decline rather than stop or reverse it. Still, after more than a century of studying a disease with no way to alter its course, even a partial success marked a historic milestone.
The history of Alzheimer’s disease is, in many ways, a story about how long it takes medicine to solve a complex problem. From Alois Alzheimer’s microscope slides in 1906 to the molecular discoveries of the 1980s to the first disease-modifying drugs over a hundred years later, progress has been painfully slow, driven by a handful of critical breakthroughs separated by long stretches of frustration. Each chapter has reshaped how scientists, doctors, and the public understand what it means to lose your memory, and whether anything can be done about it.